Basic Information
OLICLINOMEL N7-1000 E EMULSION FOR INFUSION
EMULSION
Regulatory Information
SIN12539P
May 6, 2004
General Sale List
Therapeutic
INTRAVENOUS
August 10, 2023
May 30, 2025
XB05BA10
Company Information
BAXTER HEALTHCARE (ASIA) PTE LTD
BAXTER HEALTHCARE (ASIA) PTE LTD
Active Ingredients
Strength: 2.14 g/l
Strength: 2.90 g/l
Strength: 1.60 g/l
Strength: 2.24 g/l
Strength: 1.79 g/l
Strength: 0.30 g/l
Strength: 2.32 g/l
Strength: 0.16 g/l
Strength: 2.40 g/l
Strength: 0.72 g/l
Strength: 40.00 g/l
Strength: 4.12 g/l
Strength: 4.60 g/l
Strength: 2.00 g/l
Strength: 0.45 g/l
Strength: 2.72 g/l
Strength: 2.45 g/l
Strength: 2.92 g/l
Strength: 8.28 g/l
Strength: 176.00 g/l
Strength: 1.92 g/l
Strength: 1.68 g/l
Detailed Information
Contraindications
**4.3 Contraindications** The use of OLICLINOMEL N7-1000E is contraindicated in the following situations: - In premature neonates, infants and children less than 2 years old, as the calorie‐nitrogen ratio and energy supply are inappropriate; - Hypersensitivity to egg, soya-bean, peanut proteins, or corn/corn products (see Section 4.4 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_), or to any other active substance or excipients listed in section 6.1 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_; - Congenital abnormalities of amino acid metabolism; - Severe hyperlipidaemia or severe disorders of lipid metabolism characterized by hypertriglyceridaemia; - Severe hyperglycaemia; - Pathologically elevated plasma concentrations of sodium, potassium, magnesium, calcium and/or phosphorus.
Indication Information
**4.1 Therapeutic indications** Parenteral nutrition for adults and children greater than two years of age, when oral or enteral nutrition is impossible, insufficient or contraindicated.